JP2022541550A5 - - Google Patents
Info
- Publication number
- JP2022541550A5 JP2022541550A5 JP2022503463A JP2022503463A JP2022541550A5 JP 2022541550 A5 JP2022541550 A5 JP 2022541550A5 JP 2022503463 A JP2022503463 A JP 2022503463A JP 2022503463 A JP2022503463 A JP 2022503463A JP 2022541550 A5 JP2022541550 A5 JP 2022541550A5
- Authority
- JP
- Japan
- Prior art keywords
- level
- upper limit
- less
- pharmaceutical composition
- reference range
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962876176P | 2019-07-19 | 2019-07-19 | |
| US62/876,176 | 2019-07-19 | ||
| US202063047822P | 2020-07-02 | 2020-07-02 | |
| US63/047,822 | 2020-07-02 | ||
| PCT/US2020/042820 WO2021016208A1 (en) | 2019-07-19 | 2020-07-20 | Methods of treating congenital adrenal hyperplasia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022541550A JP2022541550A (ja) | 2022-09-26 |
| JP2022541550A5 true JP2022541550A5 (cg-RX-API-DMAC7.html) | 2023-07-28 |
Family
ID=74193935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022503463A Pending JP2022541550A (ja) | 2019-07-19 | 2020-07-20 | 先天性副腎過形成を処置する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20220133742A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3986416A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022541550A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220052927A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114423436A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020318970B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022000956A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3147891A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022000812A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202116324A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021016208A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210064407A (ko) | 2014-01-21 | 2021-06-02 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 선천성 부신 과형성 치료를 위한 crf1 수용체 길항제 |
| BR112020002967A2 (pt) | 2017-08-14 | 2020-08-11 | Spruce Biosciences, Inc. | antagonistas de receptor de fator de liberação de corticotropina |
| MX2020011344A (es) | 2018-04-27 | 2021-02-09 | Spruce Biosciences Inc | Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios. |
| PL3984523T3 (pl) | 2018-12-07 | 2026-02-02 | Neurocrine Biosciences, Inc. | Antagonista receptora crf1, jego formulacje farmaceutyczne i postacie stałe do leczenia wrodzonego przerostu nadnerczy |
| US12383536B2 (en) | 2019-09-27 | 2025-08-12 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods of use |
| ES3039926T3 (en) | 2019-12-04 | 2025-10-27 | Neurocrine Biosciences Inc | Crf receptor antagonists and methods of use |
| JP2023537598A (ja) * | 2020-08-12 | 2023-09-04 | スプルース バイオサイエンシーズ,インク. | 多嚢胞性卵巣症候群を処置するための方法および組成物 |
| US20240024330A1 (en) * | 2020-08-26 | 2024-01-25 | Neurocrine Biosciences, Inc. | Crf receptor antagonists and methods of use |
| MD20210019A2 (ro) | 2021-04-12 | 2022-10-31 | Максим МАСЮТИН | Metodă de tratament a hiperplaziei suprarenale congenitale, cauzate de deficit de 21-hidroxilază cu debut tardiv prin regimul de glucocorticoizi adaptat individual |
| EP4402142A4 (en) * | 2021-11-19 | 2025-07-23 | Spruce Biosciences Inc | CRYSTALLINE COMPOSITION OF TILDACERFONT AND ITS METHODS OF USE AND PREPARATION |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005020910A2 (en) * | 2003-08-27 | 2005-03-10 | Pharmacia Corporation | Cyclooxygenase-2 selective inhibitor and corticotropin releasing factor antagonist compositions for treating ischemic mediated cns disorders or injuries |
| US8304431B2 (en) * | 2003-12-02 | 2012-11-06 | Pharmaneuroboost N.V. | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| CN101516835A (zh) * | 2006-07-19 | 2009-08-26 | 俄亥俄州立大学研究基金会 | 选择性雄激素受体调节剂、它们的类似物和衍生物以及它们的用途 |
| KR101088239B1 (ko) * | 2006-09-20 | 2011-11-30 | 일라이 릴리 앤드 캄파니 | Crf1 수용체 길항제로서의 티아졸 피라졸로피리미딘 |
| JP2015516979A (ja) * | 2012-04-23 | 2015-06-18 | ホルスボールマッシュマイヤー ニューロケミー ゲーエムベーハーHolsboermaschmeyer Neurochemie Gmbh | Crh過剰活性を有する患者の治療に用いるためのcrhr1アンタゴニスト |
| KR20210064407A (ko) * | 2014-01-21 | 2021-06-02 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 선천성 부신 과형성 치료를 위한 crf1 수용체 길항제 |
| BR112020002967A2 (pt) * | 2017-08-14 | 2020-08-11 | Spruce Biosciences, Inc. | antagonistas de receptor de fator de liberação de corticotropina |
| TWI803504B (zh) * | 2017-08-14 | 2023-06-01 | 美商雲杉生物科技股份有限公司 | 促皮質素釋放因子受體拮抗劑 |
| MX2020011344A (es) | 2018-04-27 | 2021-02-09 | Spruce Biosciences Inc | Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios. |
| PL3984523T3 (pl) | 2018-12-07 | 2026-02-02 | Neurocrine Biosciences, Inc. | Antagonista receptora crf1, jego formulacje farmaceutyczne i postacie stałe do leczenia wrodzonego przerostu nadnerczy |
-
2020
- 2020-07-20 KR KR1020227005252A patent/KR20220052927A/ko not_active Ceased
- 2020-07-20 WO PCT/US2020/042820 patent/WO2021016208A1/en not_active Ceased
- 2020-07-20 TW TW109124484A patent/TW202116324A/zh unknown
- 2020-07-20 MX MX2022000812A patent/MX2022000812A/es unknown
- 2020-07-20 CN CN202080065892.7A patent/CN114423436A/zh active Pending
- 2020-07-20 AU AU2020318970A patent/AU2020318970B2/en active Active
- 2020-07-20 BR BR112022000956A patent/BR112022000956A2/pt unknown
- 2020-07-20 JP JP2022503463A patent/JP2022541550A/ja active Pending
- 2020-07-20 CA CA3147891A patent/CA3147891A1/en active Pending
- 2020-07-20 EP EP20844541.1A patent/EP3986416A4/en active Pending
-
2022
- 2022-01-18 US US17/578,149 patent/US20220133742A1/en active Pending
-
2024
- 2024-02-09 US US18/438,060 patent/US20240261300A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025020148A5 (cg-RX-API-DMAC7.html) | ||
| IL286048B2 (en) | Abiraterone decanoate and its pharmaceutical salts, pharmaceutical preparations containing them, their uses and preparation | |
| Africander et al. | Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception | |
| Regidor et al. | Antiandrogenic and antimineralocorticoid health benefits of COC containing newer progestogens: dienogest and drospirenone | |
| Sitruk-Ware | New progestogens: a review of their effects in perimenopausal and postmenopausal women | |
| CA2326654A1 (en) | Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways | |
| JP2019131587A (ja) | 子宮内膜増殖を抑制するための組成物および方法 | |
| CN1075375C (zh) | 合并应用于女性避孕的具黄体酮拮抗作用和抗雌激素作用的化合物 | |
| JP2007535922A5 (cg-RX-API-DMAC7.html) | ||
| JP2006527193A5 (cg-RX-API-DMAC7.html) | ||
| JP2011502172A5 (cg-RX-API-DMAC7.html) | ||
| JP2021512852A5 (cg-RX-API-DMAC7.html) | ||
| CN103298343A (zh) | 类固醇和糖皮质激素受体拮抗剂组合疗法 | |
| Davtyan | Four generations of progestins in oral contraceptives | |
| CN110997667A (zh) | 促肾上腺皮质激素释放因子受体拮抗剂 | |
| JP2008534533A5 (cg-RX-API-DMAC7.html) | ||
| Pluchino et al. | One-year therapy with 10 mg/day DHEA alone or in combination with HRT in postmenopausal women: effects on hormonal milieu | |
| JP2018062530A (ja) | プロゲステロン依存性病態を処置する方法およびその組成物 | |
| IL312515A (en) | Bispecific cd16a binders | |
| Schane et al. | ORAL PROGESTATIONAL ACTIVITY OF SPIRONOLACTONE1 | |
| WO2023163945A1 (en) | Treatment of congenital adrenal hyperplasia and polycystic ovary syndrome | |
| Zhu et al. | Approved Steroidal Drugs (2000–2025): A Medicinal Chemistry Perspective | |
| JP2005513024A5 (cg-RX-API-DMAC7.html) | ||
| Noori et al. | Effects of estrogen and progesterone used in oral contraceptive pills: A review | |
| IL312514A (en) | Corticosteroid reduction in treatment with anti-cd38 antibodies |